Manfredo Bruni

Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study

Tiago Torres, L. Puig, Ronald Vender et al. · American Journal of Clinical Dermatology · 2021 · 112 citations · Full text

Il-23 Inhibitors, Medicine, Drug Survival +6

Drug Survival of Interleukin (IL)‑17 and IL‑23 Inhibitors for the Treatment of Psoriasis: A Retrospective Multi‑country, Multicentric Cohort Study

Tiago Torres, L. Puig, Ronald Vender et al. · American Journal of Clinical Dermatology · 2022 · 73 citations · Full text

Inflammation, Drug Survival, Immunology +7

A case of nivolumab-induced bullous pemphigoid successfully treated with dupilumab

Manfredo Bruni, Agata Moar, Donatella Schena et al. · Dermatology Online Journal · 2022 · 25 citations · Full text

Conventional Bullous Pemphigoid, Autoimmune Disease, Scleroderma +13

Methotrexate vs secukinumab safety in psoriasis patients with metabolic syndrome

Paolo Gisondi, Francesco Bellinato, Manfredo Bruni et al. · Dermatologic Therapy · 2020 · 17 citations

Inflammation, Metabolic Syndrome, Psoriasis Patients +10

Age affects drug survival rates of interleukin (<scp>IL</scp>)‐17 and <scp>IL</scp>‐23 inhibitors in patients with plaque psoriasis: Results from a retrospective, multicentric, multi‐country, cohort study

Andrea Chiricozzi, Giulia Coscarella, L. Puig et al. · Journal of the European Academy of Dermatology and Venereology · 2024 · 12 citations